Irritable Bowel Syndrome - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 140
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I6691E4F088EN
Leaflet:

Download PDF Leaflet

Irritable Bowel Syndrome - Pipeline Review, H2 2016
Irritable Bowel Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome – Pipeline Review, H2 2016, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.Irritable Bowel Syndrome.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Irritable Bowel Syndrome Overview
Therapeutics Development
Pipeline Products for Irritable Bowel Syndrome - Overview
Irritable Bowel Syndrome - Therapeutics under Development by Companies
Irritable Bowel Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Irritable Bowel Syndrome - Products under Development by Companies
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development

4D PHARMA PLC

A. Menarini Industrie Farmaceutiche Riunite Srl
Alfa Wassermann S.p.A
Ardelyx, Inc.
Astellas Pharma Inc.
CJ HealthCare Corp.
Dong-A Socio Holdings Co. Ltd.
Enterome Bioscience SA
GlaxoSmithKline Plc
Innovative Med Concepts, LLC
Ironwood Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Lexicon Pharmaceuticals, Inc.
Napo Pharmaceuticals Inc
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
RaQualia Pharma Inc.
RedHill Biopharma Ltd.
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co Ltd
Synergy Pharmaceuticals, Inc.
Synthetic Biologics, Inc.
Vitality Biopharma Inc
Irritable Bowel Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7147 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bedoradrine sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blautix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-14199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crofelemer DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTI-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-6952 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3179106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibodutant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-4006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LX-1033 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-2952 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relenopride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00202730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00310941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solabegron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Irritable Bowel Syndrome - Dormant Projects
Irritable Bowel Syndrome - Discontinued Products
Irritable Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results
Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting
Oct 17, 2016: Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology Annual Scientific Meeting
Sep 28, 2016: Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program
Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation
Jul 19, 2016: 4D Pharma Provides Phase I Clinical Trial Update
Jul 15, 2016: Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program
Jun 20, 2016: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA for IBS-D
May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
May 23, 2016: Phase I trial Update On Blautix For The Treatment Of Irritable Bowel Syndrome : 4D pharma
May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016
May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 140

LIST OF TABLES

Number of Products under Development for Irritable Bowel Syndrome, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H2 2016
Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H2 2016
Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H2 2016
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H2 2016
Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp., H2 2016
Irritable Bowel Syndrome - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2016
Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts, LLC, H2 2016
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H2 2016
Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Irritable Bowel Syndrome - Pipeline by Pfizer Inc., H2 2016
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H2 2016
Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd., H2 2016
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H2 2016
Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Irritable Bowel Syndrome - Dormant Projects, H2 2016
Irritable Bowel Syndrome - Dormant Projects (Contd..1), H2 2016
Irritable Bowel Syndrome - Dormant Projects (Contd..2), H2 2016
Irritable Bowel Syndrome - Dormant Projects (Contd..3), H2 2016
Irritable Bowel Syndrome - Dormant Projects (Contd..4), H2 2016
Irritable Bowel Syndrome - Discontinued Products, H2 2016 125

LIST OF FIGURES

Number of Products under Development for Irritable Bowel Syndrome, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Irritable Bowel Syndrome - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: